acalyx was founded in 2019 as a spin-out of the Max-Planck-Institute of Colloids and Interfaces (MPICI) in Potsdam, Germany, with the help of Prof. Dr. Peter Seeberger and Dr. Oren Moscovitz.
We strive to develop novel anticancer therapeutics targeting Tumor Associated Carbohydrate Antigens (TACAs).